PSA Velocity Is Associated With Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness

Urology

Volumn 72, Issue 5, 2008, Pages 1116-1120

  Loeb, Stacy ^a   Sutherland, Douglas E ^b   D'Amico, Anthony V ^c   Roehl, Kimberly A ^d   Catalona, William J ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CONTROL; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 54449098163     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.01.082     Document Type: Article

References (17)

1. American Cancer Society. Cancer Facts and Figures 2007. www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf Accessed January 28, 2007
2. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
3. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
4. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
5. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 57 (2003) 944-952
6. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
7. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
8. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
9. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
10. Patel D.A., Presti Jr. J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
11. Eggener S.E., Roehl K.A., Yossepowitch O., et al. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol 176 (2006) 1399-1403
12. Smith D.S., and Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152 (1994) 1163-1167
13. Landis J.R., and Koch G.G. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33 (1977) 363-374
14. Schroder F.H., Roobol M.J., van der Kwast T.H., et al. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465
15. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
16. Berger A.P., Deibl M., Strasak A., et al. Large-scale study of clinical impact of PSA velocity: Long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69 (2007) 134-138
17. Chun F.K., Briganti A., Shariat S.F., et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int 98 (2006) 329-334